FDA Generic Final Rule Requires Polymorph Test Data For Patent Listing
This article was originally published in The Tan Sheet
Executive Summary
FDA's final rule to reform Hatch/Waxman requires an innovator company to test data to establish that a polymorph claimed in a patent is the same as the active ingredient in the NDA